METHODS: Cyclophosphamide-loaded gold/reduced graphene oxide nanocomposites (Au-rGOCP) were synthesized and evaluated using FT-IR, XRD, release pattern, and FE-SEM techniques. Furthermore, the anticancer effect against breast cancer cells was evaluated through MTT and Annexin V assays. CAT, SOD, and GPx biomarkers were used to assess the antioxidant effect of the free and nano-formulated cyclophosphamide.
RESULTS: The characterization results showed the effective loading of cyclophosphamide in the nanocarriers. Additionally, Au-rGO had a higher drug loading capacity for cyclophosphamide during a 24-hour contact period (92.34%). The pH value affected the amount of cyclophosphamide released from the nanocarriers. Au-rGO/CP displayed significant in vitro anti-cancer activity against MCF-7 cancer cells relative to free CP and rGO/CP. According to Annexin V assay results, Au-rGO/CP induced a higher apoptosis rate in MCF-7 breast cancer cells than other forms.
CONCLUSIONS: In conclusion, our findings demonstrate that the gold-decorated reduced graphene oxide nanocomposite enhances treatment efficacy and significantly increases apoptosis and cell death induction. As a result, CP-loaded Au-rGO-based compounds could be a promising treatment for breast cancer.
方法:合成了环磷酰胺负载的金/还原氧化石墨烯纳米复合材料(Au-rGOCP),并使用FT-IR进行了评估,XRD,释放模式,和FE-SEM技术。此外,通过MTT法和膜联蛋白V法评价对乳腺癌细胞的抗癌作用。CAT,SOD,和GPx生物标志物用于评估游离和纳米配制的环磷酰胺的抗氧化作用。
结果:表征结果显示环磷酰胺在纳米载体中的有效负载。此外,Au-rGO在24小时接触期间对环磷酰胺具有较高的药物负载能力(92.34%)。pH值影响从纳米载体释放的环磷酰胺的量。相对于游离CP和rGO/CP,Au-rGO/CP对MCF-7癌细胞显示出显著的体外抗癌活性。根据膜联蛋白V的检测结果,Au-rGO/CP在MCF-7乳腺癌细胞中诱导的凋亡率高于其他形式。
结论:结论:我们的研究结果表明,金修饰的还原氧化石墨烯纳米复合材料提高了治疗效果,并显着增加了细胞凋亡和细胞死亡诱导。因此,基于CP的Au-rGO化合物可能是一种有希望的乳腺癌治疗方法。